# Lixisenatide

Canonical source: https://retacompare.com/encyclopedia/lixisenatide

Short-acting GLP-1 receptor agonist with strong post-prandial glucose effect.

Reference facts

Also known asAdlyxin, LyxumiaCategoryGLP-1 & MetabolicMechanism of actionShort-acting GLP-1 receptor agonist with strong post-prandial glucose effect.TargetsGLP-1RIndications under research or approvedType 2 DiabetesRegulatory status (reference entry)FDA-approved (2016, US discontinued 2023)Half-life~3 hoursSequenceHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKKSequence notesExendin-4 analog with C-terminal six-lysine tail and Pro38 deletion.Molecular weight (Da)4858Originator / sponsorSanofiFirst reported2007
    Primary References

ELIXA CV outcomes, NEJM 2015


    Explore research articles about Lixisenatide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- ELIXA CV outcomes, NEJM 2015: https://www.nejm.org/doi/full/10.1056/NEJMoa1509225